vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and iQSTEL Inc (IQST). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $84.2M, roughly 1.7× iQSTEL Inc). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -3.2%, a 38.7% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -14.9%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-1.2M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 28.0%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
iQSTEL Inc is a technology holding company operating three core segments: telecommunications, Internet of Things (IoT), and fintech. It offers connectivity services, smart IoT monitoring solutions, and digital financial tools, mainly serving small and medium-sized enterprises and retail customers in North and South American markets.
ADMA vs IQST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $84.2M |
| Net Profit | $49.4M | $-2.7M |
| Gross Margin | 63.8% | 3.5% |
| Operating Margin | 45.1% | -2.9% |
| Net Margin | 35.5% | -3.2% |
| Revenue YoY | 18.4% | -14.9% |
| Net Profit YoY | -55.9% | -44.5% |
| EPS (diluted) | $0.20 | $-0.92 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $84.2M | ||
| Q3 25 | $134.2M | $102.9M | ||
| Q2 25 | $122.0M | $72.2M | ||
| Q1 25 | $114.8M | $57.6M | ||
| Q4 24 | $117.5M | $98.9M | ||
| Q3 24 | $119.8M | $54.2M | ||
| Q2 24 | $107.2M | $78.6M | ||
| Q1 24 | $81.9M | $51.4M |
| Q4 25 | $49.4M | $-2.7M | ||
| Q3 25 | $36.4M | $-2.3M | ||
| Q2 25 | $34.2M | $-2.3M | ||
| Q1 25 | $26.9M | $-1.1M | ||
| Q4 24 | $111.9M | $-1.9M | ||
| Q3 24 | $35.9M | $-773.0K | ||
| Q2 24 | $32.1M | $-2.0M | ||
| Q1 24 | $17.8M | $-580.2K |
| Q4 25 | 63.8% | 3.5% | ||
| Q3 25 | 56.3% | 2.7% | ||
| Q2 25 | 55.1% | 2.6% | ||
| Q1 25 | 53.2% | 3.4% | ||
| Q4 24 | 53.9% | 2.7% | ||
| Q3 24 | 49.8% | 3.7% | ||
| Q2 24 | 53.6% | 2.8% | ||
| Q1 24 | 47.8% | 2.7% |
| Q4 25 | 45.1% | -2.9% | ||
| Q3 25 | 38.0% | -0.5% | ||
| Q2 25 | 35.1% | -0.9% | ||
| Q1 25 | 30.4% | -1.0% | ||
| Q4 24 | 32.6% | -0.3% | ||
| Q3 24 | 33.1% | -0.1% | ||
| Q2 24 | 36.6% | -0.4% | ||
| Q1 24 | 26.7% | -0.4% |
| Q4 25 | 35.5% | -3.2% | ||
| Q3 25 | 27.1% | -2.3% | ||
| Q2 25 | 28.1% | -3.3% | ||
| Q1 25 | 23.4% | -2.0% | ||
| Q4 24 | 95.2% | -1.9% | ||
| Q3 24 | 30.0% | -1.4% | ||
| Q2 24 | 29.9% | -2.5% | ||
| Q1 24 | 21.7% | -1.1% |
| Q4 25 | $0.20 | $-0.92 | ||
| Q3 25 | $0.15 | $-0.68 | ||
| Q2 25 | $0.14 | $-0.82 | ||
| Q1 25 | $0.11 | $-0.44 | ||
| Q4 24 | $0.45 | $-1.19 | ||
| Q3 24 | $0.15 | $-0.40 | ||
| Q2 24 | $0.13 | $-0.90 | ||
| Q1 24 | $0.08 | $-0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $2.2M |
| Total DebtLower is stronger | $72.1M | $4.1M |
| Stockholders' EquityBook value | $477.3M | $16.3M |
| Total Assets | $624.2M | $51.1M |
| Debt / EquityLower = less leverage | 0.15× | 0.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $2.2M | ||
| Q3 25 | $61.4M | $2.3M | ||
| Q2 25 | $90.3M | $2.0M | ||
| Q1 25 | $71.6M | $1.1M | ||
| Q4 24 | $103.1M | $2.5M | ||
| Q3 24 | $86.7M | $2.1M | ||
| Q2 24 | $88.2M | $797.2K | ||
| Q1 24 | $45.3M | $2.7M |
| Q4 25 | $72.1M | $4.1M | ||
| Q3 25 | $72.4M | $2.7M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $3.5M | ||
| Q4 24 | $72.3M | $2.5M | ||
| Q3 24 | — | $3.2M | ||
| Q2 24 | — | $2.5M | ||
| Q1 24 | — | $194.0K |
| Q4 25 | $477.3M | $16.3M | ||
| Q3 25 | $431.2M | $17.9M | ||
| Q2 25 | $398.3M | $14.3M | ||
| Q1 25 | $373.4M | $11.6M | ||
| Q4 24 | $349.0M | $11.9M | ||
| Q3 24 | $231.9M | $8.1M | ||
| Q2 24 | $188.3M | $7.6M | ||
| Q1 24 | $153.7M | $8.4M |
| Q4 25 | $624.2M | $51.1M | ||
| Q3 25 | $568.7M | $46.9M | ||
| Q2 25 | $558.4M | $51.4M | ||
| Q1 25 | $510.6M | $42.0M | ||
| Q4 24 | $488.7M | $79.0M | ||
| Q3 24 | $390.6M | $32.4M | ||
| Q2 24 | $376.4M | $30.0M | ||
| Q1 24 | $350.9M | $22.1M |
| Q4 25 | 0.15× | 0.25× | ||
| Q3 25 | 0.17× | 0.15× | ||
| Q2 25 | — | 0.31× | ||
| Q1 25 | — | 0.31× | ||
| Q4 24 | 0.21× | 0.21× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $-1.2M |
| Free Cash FlowOCF − Capex | $34.6M | $-1.2M |
| FCF MarginFCF / Revenue | 24.8% | -1.5% |
| Capex IntensityCapex / Revenue | 0.8% | 0.0% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $-4.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $-1.2M | ||
| Q3 25 | $13.3M | $-953.0K | ||
| Q2 25 | $21.1M | $257.7K | ||
| Q1 25 | $-19.7M | $-1.9M | ||
| Q4 24 | $50.2M | $-403.7K | ||
| Q3 24 | $25.0M | $625.0K | ||
| Q2 24 | $45.6M | $-2.6M | ||
| Q1 24 | $-2.2M | $-536.9K |
| Q4 25 | $34.6M | $-1.2M | ||
| Q3 25 | $-1.1M | $-969.2K | ||
| Q2 25 | $18.7M | $211.7K | ||
| Q1 25 | $-24.4M | $-2.0M | ||
| Q4 24 | $47.5M | $-421.3K | ||
| Q3 24 | $24.0M | $594.5K | ||
| Q2 24 | $43.6M | $-2.6M | ||
| Q1 24 | $-4.6M | $-608.5K |
| Q4 25 | 24.8% | -1.5% | ||
| Q3 25 | -0.8% | -0.9% | ||
| Q2 25 | 15.3% | 0.3% | ||
| Q1 25 | -21.2% | -3.4% | ||
| Q4 24 | 40.4% | -0.4% | ||
| Q3 24 | 20.0% | 1.1% | ||
| Q2 24 | 40.7% | -3.4% | ||
| Q1 24 | -5.6% | -1.2% |
| Q4 25 | 0.8% | 0.0% | ||
| Q3 25 | 10.7% | 0.0% | ||
| Q2 25 | 2.0% | 0.1% | ||
| Q1 25 | 4.1% | 0.1% | ||
| Q4 24 | 2.3% | 0.0% | ||
| Q3 24 | 0.9% | 0.1% | ||
| Q2 24 | 1.9% | 0.0% | ||
| Q1 24 | 2.9% | 0.1% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
IQST
| USA | $53.2M | 63% |
| Other | $29.9M | 35% |
| Switzerland | $1.1M | 1% |
